logo-loader
viewSynairgen PLC

Synairgen to start trials this week of its lead drug in patients with COVID-19

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott they've received approval to launch a phase II clinical trial of its lead drug in patients with COVID-19.

SNG001 is an inhaled formulation of interferon-beta-1a and is currently being developed to treat people with chronic obstructive pulmonary disease (COPD) that also have respiratory viral infections.

Quick facts: Synairgen PLC

Price: 41.5 GBX

AIM:SNG
Market: AIM
Market Cap: £62.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 rises on Europe’s coronavirus bailout and US...

Headlines from the Proactive UK newsroom. The FTSE 100 rose again as investors welcomed Europe’s coronavirus bailout and the US gave more details on its reopening plans for non-essential businesses. The blue-chip index added 42 points to 6,187. Roche and Gilead are combining their two...

4 days, 12 hours ago

2 min read